FDA Clinical Hold Removed for Histogen Trial in Knee Regeneration

Histogen confirmed that the company has satisfactorily addressed all clinical hold questions and can proceed with a planned Phase I/II clinical trial of human extracellular matrix (hECM:HST-003), implanted within microfracture interstices and the cartilage defect in the knee, to regenerate hyaline cartilage in combination with...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us